Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 May 1;15(9):2174-83.

Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation

G Bunone  1 , P A Briand, R J Miksicek, D Picard
Affiliations

Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation

G Bunone et al. EMBO J. .

Abstract

The estrogen receptor (ER) can be activated as a transcription factor either by binding of cognate estrogenic ligand or, indirectly, by a variety of other extracellular signals. As a first step towards elucidating the mechanism of 'steroid-independent activation' of the ER by the epidermal growth factor (EGF), we have mapped the ER target domain and determined the signaling pathway. We show that the N-terminal transcriptional activation function AF-1, but not the C-terminal AF-2, is necessary for the EGF response. Both the EGF-induced hyperphosphorylation and the transcriptional activation of the unliganded ER depend on a phosphorylatable serine residue at position 118. However, its phosphorylation is not sufficient and, hence, there must be other target domains or proteins which fulfill an additional requirement for EGF signaling through the ER. Using dominant-negative Ras and MAP kinase kinase (MAPK kinase) and constitutively active MAPK kinase mutants, we show that EGF activates the ER by signaling through the MAPK pathway suggesting that MAPK directly phosphorylates the critical serine 118. Our results also imply that the steroid-independent activation of a variety of ER mutants, which arise during the malignant progression of breast tumors, may contribute to tamoxifen resistance.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Steroid Biochem Mol Biol. 1994 Apr;48(5-6):481-6 - PubMed
    1. EMBO J. 1987 May;6(5):1309-15 - PubMed
    1. J Biol Chem. 1995 Mar 10;270(10):5594-9 - PubMed
    1. Breast Cancer Res Treat. 1994;32(1):49-55 - PubMed
    1. Science. 1993 Nov 12;262(5136):1069-72 - PubMed

Publication types